A host of biotechnology companies are racing to develop new therapies that ultimately aim to go beyond merely treating symptoms to attacking the cause of diabetes. Many diabetes patients could have the option within two or three years, of inhaling insulin rather than giving themselves injections. But not long after that, if all goes well, new oral drugs could postpone or even prevent the need for some to use insulin.